Table 1.
Summary of clinico-pathologic characteristics (N = 613)
Table 2.
Immunohistochemistry results and biochemical recurrence rate for ERG and PTEN expression (N = 613).
Fig 1.
Representative immunohistochemistry for ERG and PTEN in prostate cancer.
(A) ERG negative, (B) weak, (C) moderate, and (D) strong, and (E) PTEN negative, (F) weak, (G) moderate, and (H) strong, respectively. (x40).
Table 3.
Correlation analysis of clinicopathological parameters to ERG and PTEN expression.
Fig 2.
Biochemical recurrence free survival curve according to expression of ERG and PTEN.
Table 4.
Association of clinico-pathologic parameters and immunostains with biochemical recurrence free survival based on Cox Proportional Hazards Regression Models.